Lv71
3780 积分 2025-06-18 加入
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso
2小时前
已关闭
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
3小时前
已完结
Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
3小时前
已完结
Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma
3小时前
已完结
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma
3小时前
已完结
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention
3小时前
已完结
[Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma]
3小时前
已完结
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso
3小时前
已完结
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
3小时前
已完结
Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
3小时前
已完结
皖公网安备34019202002308
